One "Nuclear" Label, Two Different Value Tests: Worley and Silex

A recent roundup of Australian nuclear stocks to watch puts Worley alongside companies whose businesses it does not resemble, and the compression is revealing. Nuclear is not one investment. It is a value chain, and the business at each layer is valued by a different test. Take the two names the article actually profiles: Worley, the global engineering-services firm, and Silex Systems, the laser-enrichment technology licensor. One is a provable cash-flow business you can stress-test today. The other is an option on a plant that does not exist yet, whose entire worth sits in future royalty checks. The label makes them siblings; the value test makes them strangers.

What Worley actually sells

Worley's nuclear exposure is real but incidental. The company engineers and services projects across energy, chemicals, and resources worldwide, and its low-carbon segment handles reactor design support, licensing, and end-of-life decommissioning. That is a slice of a project-services business whose economics are set by backlog and margins, not by the uranium price. Its customers' capital cycles, not the spot market, drive its results.

Those results just deteriorated. For fiscal 2026 Worley reported aggregated revenue of A$12.0 billion, broadly flat, while underlying EBITA fell 10.8% to A$734 million and statutory profit shrank by more than a third, to about A$306 million. Management blamed A$58 million of damage from the Middle East conflict and A$50 million of currency translation. The market's verdict was blunt: the shares fell 11.5% to roughly A$9.82 in the session after results, near their 52-week low, leaving a stock that trades below book value with a dividend yield near 5%.

For a value investor the question is not whether the headline fell but whether the business still services its obligations and sustains its payout. On that score the evidence is mixed. Cash conversion was strong at 93.6%, leverage sat at 1.8x against a 2x target on an investment-grade balance sheet, and the company kept returning capital—A$359 million returned to shareholders over the year. The dividend, about A$0.50 a share and unfranked at the final payment, is not well covered by earnings; it rides on backlog conversion and cash flow rather than clearing comfortably through profit. Backlog was A$13.8 billion, down from A$16.7 billion at the half-year, though 62% is slated for delivery in fiscal 2027 and bookings hit A$15.5 billion. This is a dividend that can be tested now, on margin recovery and payout coverage, against a balance sheet that can absorb the near-term pain. That is a real value question, answerable with evidence.

What Silex actually owns

Silex is a different species. It is a technology commercialization company—the licensor of the SILEX laser enrichment process—with roughly a A$1.4 billion market value, revenue in the tens of millions of dollars, no profit, and no dividend. Its stake in the commercial venture, Global Laser Enrichment (51%, with Cameco at 49% and an option to raise its interest to 75% and dilute Silex), entitles it to a perpetual minimum 7% royalty on future enrichment revenue plus milestone payments. Every dollar of Silex's value is downstream of a plant that has not been financed or built.

The notable development is real. On September 14 Cameco signed an exclusive offtake to buy every pound of output from the planned Paducah Laser Enrichment Facility at Cameco's own average realized long-term price. That gives the technology its first complete commercial demand anchor before a final investment decision. It removes one risk.

It does not remove the others. A final investment decision has not been taken; the sequence still requires a successful large-scale technology demonstration, a feasibility assessment, and a Nuclear Regulatory Commission license application that is currently on hold, plus government support, with commercial operation aimed no later than 2030—and Cameco can raise its stake to 75% as the project develops. The offtake is a pillar for a future decision, not a revenue line today. The near-total gap between a ~A$1.4 billion price and current cash flow explains why the stock can swing from about A$3.86 to A$10.85 within a year: what it is worth depends entirely on assumptions about a 2030 plant's throughput, pricing, and timing that no one can verify yet. That is the chessboard of a call option, not the floor of a business.

The test, matched to the layer

The lesson the roundup obscures is that valuation method follows where a company sits in the chain. A uranium producer's value is downstream of the fuel price, so the first test is commodity downside. An enrichment licensor's value is downstream of commercialization, so the first test is deliverability. An engineering-services firm's value is downstream of project backlog and margins, so the first test is payout durability through the cycle.

Nuclear exposure is not a portfolio slot. Worley can stand as an income candidate only to the extent its margin recovers and its roughly 5% dividend stays covered through the project cycle it just entered; Silex is a speculation on an unproven technology and must be sized as one, gated on a final investment decision and a license. A price attached to provable cash flow is value. A price attached to a future that has not happened is an option—and only the former has the floor the label implies.